Skip to main content
. 2019 May 23;40(6):728–735. doi: 10.1097/MAO.0000000000002287

TABLE 1.

Clinical characteristics of bilateral sudden sensorineural hearing loss participants according to serum total bilirubin tertiles

TBIL (μmol/L)
Variables Overall T1 (<10.6) T2 (10.6–13.4) T3 (>13.4)# p
Number of participants 113 40 38 35
TBIL (μmol/L)* 11.9 (4.2) 7.8 (1.9) 11.9 (0.9) 16.6 (3.1) <0.001a
DBIL (μmol/L)* 3.2 (1.2) 2.3 (0.9) 3.2 (0.8) 4.3 (1.1) <0.001a
Age (yrs)* 51.0 (38.0–58.0) 47.5 (33.8–59.2) 51.0 (39.8–56.8) 52.0 (42.2–62.0) 0.490
Gender* 0.003b
 Female 45 (39.8%) 24 (60.0%) 13 (34.2%) 8 (22.9%)
 Male 68 (60.2%) 16 (40.0%) 25 (65.8%) 27 (77.1%)
Neutrophil (103/μl)* 4.0 (3.0–5.7) 4.1 (3.0–6.9) 3.8 (2.9–4.8) 4.1 (3.0–5.6) 0.650
Lymphocyte (103/μl)* 2.1 (1.6–2.4) 2.2 (1.5–2.7) 2.1 (1.8–2.4) 1.9 (1.4–2.3) 0.308
RBC (106/μl)* 4.6 (0.5) 4.5 (0.5) 4.6 (0.5) 4.7 (0.4) 0.027c
Hemoglobin (g/L)* 139.7 (16.6) 133.1 (17.8) 142.5 (14.0) 144.1 (15.8) 0.006c
Platelet (103/μl)* 225.5 (53.6) 241.4 (61.8) 211.4 (52.3) 222.8 (39.6) 0.042d
Hemocrit* 0.41 (0.05) 0.39 (0.05) 0.42 (0.04) 0.42 (0.04) 0.005c
GGT (U/L)* 23.1 (15.7–35.4) 18.4 (12.4–25.2) 23.6 (17.5–33.0) 27.0 (19.0–45.0) 0.011e
ALP (U/L)* 64.9 (53.4–74.6) 66.0 (55.1–92.4) 56.9 (50.9–73.2) 65.6 (59.5–68.5) 0.061
Mg (mmol/L)* 0.89 (0.07) 0.87 (0.07) 0.88 (0.07) 0.92 (0.06) 0.020e
TG (mmol/L)* 1.4 (0.9–1.9) 1.3 (0.7–1.6) 1.6 (0.7) 1.6 (0.7) 0.055
LDL (mmol/L)* 3.0 (0.8) 2.8 (0.8) 3.0 (0.8) 3.2 (0.9) 0.191
HDL (mmol/L)* 1.3 (1.1–1.5) 1.4 (1.1–1.7) 1.2 (1.0–1.5) 1.3 (1.2–1.5) 0.790
Treatment (d)*
 Local steroids 1.0 (0.0–3.0) 2.0 (0.0–3.0) 1.0 (0.0–3.0) 1.0 (0.0–3.0) 0.488
 Systemic steroids 0.0 (0.0–5.0) 0.0 (0.0–4.0) 0.0 (0.0–6.0) 0.0 (0.0–5.5) 0.648
 Batroxobin 4.0 (2.0–5.0) 5.0 (2.0–5.2) 4.0 (3.0–5.0) 3.0 (1.0–5.0) 0.101
 EGb761 10.0 (6.0–13.0) 11.0 (8.5–13.2) 10.0 (6.2–12.0) 9.0 (4.5–11.5) 0.089
Number of ears 180 62 60 58
Time duration (d)Δ 10.0 (4.0–16.2) 14.0 (8.0–17.0) 7.5 (4.0–14.5) 10.0 (3.0–15.0) 0.043
Initial hearing (dB HL) 65.3 (46.7–88.4) 78.2 (58.4–98.8) 63.2 (45.0–84.1) 57.6 (44.5–75.3) 0.002c
Final hearing (dB HL) 58.3 (29.2) 67.4 (29.7) 56.6 (29.1) 50.1 (26.3) 0.004c
Relative hearing gain (dB) 10.4 (1.2–30.9) 7.1 (0.0–23.7) 12.3 (1.2–31.4) 15.7 (4.2–32.6) 0.092
Absolute hearing gain (dB) 7.3 (0.8–17.9) 4.6 (0.0–12.8) 10.0 (1.1–18.2) 8.7 (2.5–17.7) 0.283
Audiogram <0.001
 Flat 45 (25.0%) 15 (24.2%) 19 (31.7%) 11 (19.0%)
 Descending 60 (33.3%) 18 (29.0%) 19 (31.7%) 23 (39.7%)
 Cophosis 57 (31.7%) 27 (43.5%) 18 (30.0%) 12 (20.7%) b
 Irregular 9 (5.0%) 0 (0.0%) 0 (0.0%) 9 (15.5%) e
 Ascending 9 (5.0%) 2 (3.2%) 4 (6.7%) 3 (5.2%)

Continuous variables were presented as mean (standard deviation) for normal distribution, or medians (interquartile range) for non-normal distribution. Categorical variables were presented as n (%).

*These were subject-specific covariates, while the rest were ear-specific covariates.

ΔThe time elapse between symptom onset and the study entry.

#Only three out of the 113 patients had levels of TBIL above the normal range.

aSignificant differences were found in all pairs of groups after post-hoc comparison.

bThe only significant difference was between T1 and T3 groups after post-hoc comparison.

cSignificant differences were found between T1 and T2, T3 groups after post-hoc comparison.

dThe only significant difference was between T1 and T2 groups after post-hoc comparison.

eSignificant differences were found between T1, T2, and T3 groups after post-hoc comparison.

ALP indicates alkaline phosphatase; BSSHL, bilateral sudden sensorineural hearing loss; DBIL, direct bilirubin; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; IBIL, indirect bilirubin; LDL, low-density lipoprotein; Mg, magnesium; RBC, red blood cell counts; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride.